Xeris Biopharma CFO sells 5,000 shares at $8.50

The 5,000-share sale was carried out under a Rule 10b5-1 plan adopted Aug. 18, 2025, leaving him with 1,356,053 shares.

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. (XERS) reported that Chief Financial Officer Steven Pieper sold 5,000 shares of common stock on September 1, 2026 at a price of $8.50 per share. After this transaction, he directly holds 1,356,053 shares of XERS common stock. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Pieper Steven

Role See Remarks

Sold 5,000 shs ($43K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	5,000	$8.50	$43K

Holdings After Transaction: Common Stock — 1,356,053 shares (Direct)

Footnotes (1)

1. F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

Key Figures

Shares sold: 5,000 shares Sale price per share: $8.50 per share Shares owned after transaction: 1,356,053 shares +1 more

4 metrics

Shares sold 5,000 shares Common stock sale on September 1, 2026

Sale price per share $8.50 per share Common stock sale on September 1, 2026

Shares owned after transaction 1,356,053 shares Direct ownership following the reported sale

Rule 10b5-1 plan adoption date August 18, 2025 Date Steven Pieper adopted the trading plan used for this sale

Key Terms

Rule 10b5-1 trading plan, Form 4, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Form 4 regulatory

"The Form 4 reports one insider transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"5,000 shares of common stock on September 1, 2026"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did XERS report for Steven Pieper?

Xeris Biopharma Holdings, Inc. reported that Chief Financial Officer Steven Pieper sold 5,000 shares of common stock on September 1, 2026 at $8.50 per share under a pre-established Rule 10b5-1 trading plan.

How many XERS shares does Steven Pieper hold after this sale?

After the reported sale, Steven Pieper directly holds 1,356,053 shares of Xeris Biopharma Holdings, Inc. common stock, as disclosed in the Form 4 filing.

Was the XERS insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Steven Pieper on August 18, 2025.

What price did Steven Pieper receive per XERS share in this transaction?

The sale was executed at a price of $8.50 per share for the 5,000 shares of Xeris Biopharma Holdings, Inc. common stock reported in the Form 4.

How many XERS insider sell transactions are reported in this Form 4?

The Form 4 reports one insider transaction: a sale of 5,000 shares of Xeris Biopharma Holdings, Inc. common stock by Chief Financial Officer Steven Pieper.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 06:21 PM EDT Accepted by SEC EDGAR 09/01/2026 - 06:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pieper Steven

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S(1)		5,000	D	$8.5	1,356,053	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

Remarks:

Chief Financial Officer

	/s/ Beth Hecht, Attorney-in-Fact	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)